SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors
H Lu, C Liu, R Velazquez, H Wang, LM Dunkl… - Molecular cancer …, 2019 - AACR
FGFR1 was recently shown to be activated as part of a compensatory response to prolonged
treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic …
treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic …
SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS-mutant tumors treated with MEK inhibitors
H Lu, C Liu, R Velazquez… - Molecular cancer …, 2019 - mdanderson.elsevierpure.com
FGFR1 was recently shown to be activated as part of a extent in those harboring the G13D
variant, and involves compensatory response to prolonged treatment with the MEK several …
variant, and involves compensatory response to prolonged treatment with the MEK several …
SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors
H Lu, C Liu, R Velazquez, H Wang… - Molecular cancer …, 2019 - oak.novartis.com
FGFR1 was recently shown to be activated as part of a compensatory response to prolonged
treatment with MEK inhibitor trametinib in several KRAS mutant lung and pancreatic cancer …
treatment with MEK inhibitor trametinib in several KRAS mutant lung and pancreatic cancer …
SHP2 inhibition overcomes RTK-mediated pathway reactivation in KRAS mutant tumors treated with MEK inhibitors
H Lu, C Liu, R Velazquez, H Wang, LM Dunkl… - Cancer Research, 2019 - AACR
Introduction: FGFR1 was recently shown to be activated as part of a compensatory response
to prolonged treatment with MEK inhibitor (MEKi) such as trametinib in several KRAS mutant …
to prolonged treatment with MEK inhibitor (MEKi) such as trametinib in several KRAS mutant …
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
H Lu, C Liu, R Velazquez, H Wang… - Molecular cancer …, 2019 - pubmed.ncbi.nlm.nih.gov
FGFR1 was recently shown to be activated as part of a compensatory response to prolonged
treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic …
treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic …
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
H Lu, C Liu, R Velazquez, H Wang, LM Dunkl… - Molecular Cancer …, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> FGFR1 was recently shown to be activated as
part of a compensatory response to prolonged treatment with the MEK inhibitor trametinib in …
part of a compensatory response to prolonged treatment with the MEK inhibitor trametinib in …
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
H Lu, C Liu, R Velazquez, H Wang… - Molecular Cancer …, 2019 - europepmc.org
FGFR1 was recently shown to be activated as part of a compensatory response to prolonged
treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic …
treatment with the MEK inhibitor trametinib in several KRAS-mutant lung and pancreatic …
SHP2 inhibition overcomes RTK-mediated pathway re-activation in KRAS mutant tumors treated with MEK inhibitors
H Lu, C Liu, R Velazquez, H Wang… - Molecular cancer …, 2019 - oak.novartis.com
FGFR1 was recently shown to be activated as part of a compensatory response to prolonged
treatment with MEK inhibitor trametinib in several KRAS mutant lung and pancreatic cancer …
treatment with MEK inhibitor trametinib in several KRAS mutant lung and pancreatic cancer …